David Rosmarin, Dermatology Meeting News 2022: Ruxolitinib Cream Monotherapy for the Treatment of Vitiligo
We were delighted to talk with Dr. David Rosmarin (Tufts Medical Center, Boston, MA, USA) to discuss the efficacy and safety findings of the TRuE-V1 and TRuE-V2 studies, investigating ruxolitinib cream monotherapy for the treatment of vitiligo.
The abstract ‘Efficacy and Safety of Ruxolitinib Cream Monotherapy for the Treatment of Vitiligo: Results From Two 52-Week Phase 3 Studies’ was presented at AAD-VMX 2022, 25-29 March.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.
- What is the rationale for the use of ruxolitinib cream in the treatment of vitiligo? (0:13)
- What were the aims, design and eligibility criteria of the TRuE-V1 and TRuE-V2 studies? (0:45)
- What were the efficacy and safety findings of these studies? (2:00)
- If approved, what will be the impact of ruxolitinib cream on the treatment of patients with vitiligo? (3:16)
- Which patients are most likely to respond to this treatment? (3:40)
- What future studies are planned? (4:24)
Disclosures: David Rosmarin discloses consulting for AbbVie, Abcuro, AltruBio, Arena, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceuticals, UCB, VielaBio; grant/ research support from AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals; and participating in speaker’s bureaus for AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.
Share this Video
Related Videos In Dermatological Conditions
Claudia De La Cruz, Dermatology Meeting News 2023: Effisayil 1 – a phase 2 study of spesolimab for generalized pustular psoriasis
Effisayil 1 (NCT03782792) was a randomised, double-blind, placebo-controlled phase 2 study that investigated the efficacy and safety of spesolimab in generalized pustular psoriasis (GPP). touchIMMUNOLOGY were delighted to speak with Dr. Claudia De La Cruz (Clínica Dermacross, Santiago, Chile) to discuss the aims, design and findings from Effisayil 1 and the impact spesolimab has already […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prevalence, clinical presentations & impact on quality of life
Pemphigus is a rare autoimmune blistering disease, which results in painful blisters on the skin or mucous membranes, severely impacting patient quality of life. It was a pleasure to talk with Prof. Dedee F. Murrell (St George Hospital Campus, Kogarah, Sydney, Australia) around the prevalence, clinical presentations and impact of pemphigus on patient quality of […]
Dedee Murrell, Dermatology Meeting News 2023: Pemphigus – prognosis, current treatment paradigm & pipeline therapies
The treatment paradigm for pemphigus remains with many unmet needs, the current standard of care remains to be systemic corticosteroids, which cause many phycological and metabolic side effects, in the past few years rituximab has been approved alongside steroids; however takes months to work. touchIMMUNOLOGY were delighted to talk with Prof. Dedee F. Murrell (St […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!